An Overview of UBTF Neuroregression Syndrome
Brain Sciences · 15.02.2024 · 14 (2) · 179
DOI: 10.3390/brainsci14020179 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 15.02.2024. Verfasst von Anneliesse A Braden und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38104, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, National Institute of Health.
Abstract (Originalsprache)
Recently, a recurrent de novo dominant mutation in UBTF (c.628G>A, p.Glu210Lys; UBTF E210K) was identified as the cause of a neurological disorder which has been named UBTF Neuroregression Syndrome (UNS), or Childhood-Onset Neurodegeneration with Brain Atrophy (CONDBA). To date, only 17 cases have been reported worldwide. The molecular etiology is a pathogenic variant, E210K, within the HMG-box 2 of Upstream Binding Transcription Factor (UBTF). UBTF, a nucleolar protein, plays an important role in ribosomal RNA (rRNA) synthesis, nucleolar integrity, and cell survival. This variant causes unstable preinitiation complexes to form, resulting in altered rDNA chromatin structures, rRNA dysregulation, DNA damage, and ultimately, neurodegeneration. Defining clinical characteristics of the disorder include but are not limited to developmental regression beginning at approximately three years of age, progressive motor dysfunction, declining cognition, ambulatory loss, and behavioral problems. Histological and neuroimaging abnormalities include cortical atrophy, white matter deficits, and enlarged ventricles. Herein, we present a detailed overview of all published cases as well as the functional roles of UBTF to better understand the pathophysiology. Bringing undiagnosed cases to the attention of clinicians and researchers by making them aware of the clinical features will improve research and support the development of therapeutic interventions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38104, USA.
- Neuroscience Institute, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
- Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
- Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
- Division of Regenerative and Rehabilitation Sciences, Department of Physical Therapy, Center for Muscle, Metabolism and Neuropathology, College of Health Professions, University of Tennessee Health Science Center, Memph…
ORCID-Profile: Anneliesse A Braden, Mohammad Moshahid Khan
Förderung
- NINDS NIH HHS
- National Institute of Health
Zitieren
APA
Braden, A. A., Xiao, J., Hori, R., Brown, C., & Khan, M. M. (2024). An Overview of UBTF Neuroregression Syndrome. Brain Sciences, 14(2), 179. https://doi.org/10.3390/brainsci14020179
Vancouver
Braden AA, Xiao J, Hori R, Brown C, Khan MM. An Overview of UBTF Neuroregression Syndrome. Brain Sciences. 2024;14(2):179. doi:10.3390/brainsci14020179
BibTeX
@article{Braden2024,
author = {Braden, Anneliesse A and Xiao, Jianfeng and Hori, Roderick and Brown, Chester and Khan, Mohammad Moshahid},
title = {An Overview of UBTF Neuroregression Syndrome},
journal = {Brain Sciences},
year = {2024},
volume = {14},
number = {2},
pages = {179},
doi = {10.3390/brainsci14020179}
}
EUVIMED